CONCLUSION:
Our Cohort of MIS-N is the largest reported as per current literature
data. MIS-N occurs as a syndrome which occurs post-exposure to
SARS-CoV2, manifests with a variety of clinical symptoms. The diagnosis
of MIS-N can be challenging and needs a high index of suspicion, after
all other potential etiologies have been excluded. MIS-N can be
considered in a neonate presenting with two or more systems involvement,
in the presence of SARS-CoV2 antibodies, along with elevated
inflammatory markers. In such cases neonatologists should perform
specific investigations such as SARS-CoV2 antigen and antibodies,
inflammatory markers routinely along with cardiac biomarkers like Pro
BNP, LDH, and early ECHO screening to evaluate myocardial dysfunction
when needed. Immunomodulator therapy should be given only for severe
cases where definitive criteria of MIS-N are met.